Item 3.01 Failure to Satisfy a Continued Listing Rule or Standard; Transfer of
Listing or Notice of Delisting.
On January 7, 2019, InspireMD, Inc. (the "Company") received notification (the
"Deficiency Letter") from the NYSE American LLC ("NYSE American") that the
Company is not in compliance with certain NYSE American continued listing
standards (the "Listing Standards"). This was in addition to the Company's prior
disclosed non-compliance with Sections 1003(a)(ii)-(iii) of the NYSE American
The Deficiency Letter states that the Company's shares of common stock have been
selling for a low price per share for a substantial period of time. Pursuant to
Section 1003(f)(v) of the NYSE American Company Guide, the NYSE American staff
determined that the Company's continued listing is predicated on it effecting a
share consolidation or otherwise demonstrating sustained price improvement
within a reasonable period of time, which the NYSE American staff determined to
be until July 7, 2019. The Company intends to regain compliance with the Listing
Standards by undertaking a measure or measures that are for the best interests
of the Company and its stockholders.
The Company's common stock will continue to be listed on the NYSE American while
it attempts to regain compliance with the Listing Standards, subject to the
Company's compliance with other continued listing requirements, as described in
prior filings. The Deficiency Letter does not affect the Company's business
operations or its Securities and Exchange Commission reporting requirements.
Item 8.01 Other Events.
On January 11, 2019, the Company issued a press release disclosing receipt of
the Deficiency Letter from the NYSE American. A copy of the press release is
attached as Exhibit 99.1 to this Current Report on Form 8-K and is hereby
incorporated by reference herein.
Item 9.01 Financial Statements and Exhibits.
99.1 Press release dated January 11, 2019
© Edgar Online, source Glimpses